TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03427736

Intervention type: DRUG
Intervention: Ketorolac Tromethamine
Description: IV ketorolac will be given per standard of care, not prescribed for this study

Intervention type: DRUG
Intervention: Hydromorphone
Description: IV Hydromorphone will be given per standard of care, not prescribed for this study

Intervention type: DRUG
Intervention: Ketamine
Description: IV Ketamine will be given per standard of care, not prescribed for this study

Intervention type: DRUG
Intervention: Oxycodone
Description: PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study

Intervention type: DRUG
Intervention: Morphine
Description: IV Morphine will be given per standard of care, not prescribed for this study
Study: NCT06035770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (educational training program)
Description: The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors.
Study: NCT03534336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for Education
Description: A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for Weight Loss
Description: A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program
Study: NCT01552707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XCEL-MT-OSTEO-ALPHA
Description: Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Instrumented spinal fusion together with patient's bone iliac crest
Study: NCT03752411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research Bottle
Description: The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular prescription Bottle
Description: This will test if the research bottle changes behavior relative to the research bottle
Study: NCT00284492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional chinese medicine type acupuncture
Description: 10 acupuncture sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Care
Description: Lifestyle advice on diet, physical activity
Study: NCT03207919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby Project
Description: Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
Study: NCT04315974

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban therapy for at least 4 weeks.

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Radiofrequency catheter ablation or cryoballoon ablation.
Study: NCT01136278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 150 μg per os
Study: NCT01046188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Description: Administered after the intervention and at study completion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based IVF teaching
Description: Web-based IVF teaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic lecture
Description: Didactic lecture
Study: NCT03217760

Intervention type: PROCEDURE
Intervention: Endodontic treatment
Description: Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
Study: NCT02323061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCI using EEG signals
Description: A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
Study: NCT01136278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules identical to MDMA or clonidine
Study: NCT02078973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 mg tolvaptan
Description: 15 mg pr day for 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg tolvaptan
Description: 30 mg pr day for 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 45 mg tolvaptan
Description: 45 mg pr day for 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk pr day for 1 day
Study: NCT04252521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: 10 mg Metpamid in 100 ml normal saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexketoprofen trometamol
Description: 50 mg dexketoprofen trometamol in 100 ml normal saline solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide+dexketoprofen trometamol
Description: 10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
Study: NCT02410785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyglucosamine
Description: ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
Study: NCT03217760

Intervention type: OTHER
Intervention: VAS of stress
Description: The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
Study: NCT02410785

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03217760

Intervention type: OTHER
Intervention: VAS of stress
Description: The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)

Intervention type: OTHER
Intervention: CORAH scale
Description: At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).

Intervention type: OTHER
Intervention: HAD Scale
Description: At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.

Intervention type: OTHER
Intervention: HAD Scale
Description: At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.

Intervention type: OTHER
Intervention: Cardiovascular Parameters
Description: For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.

Intervention type: OTHER
Intervention: Cardiovascular Parameters
Description: For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.

Intervention type: OTHER
Intervention: Cortisol Measurements
Description: Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .

Intervention type: OTHER
Intervention: Cortisol Measurements
Description: Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .

Intervention type: OTHER
Intervention: Discomfort and Pain Experienced During Treatment
Description: Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.

Intervention type: OTHER
Intervention: Patient's preferences.
Description: After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.

Intervention type: OTHER
Intervention: student preferences.
Description: When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment.
Study: NCT03162289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan
Description: Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
Study: NCT03114748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Study: NCT03467230

Intervention type: DEVICE
Intervention: NoL Index
Description: Use of the PMD-200 in an observational study
Study: NCT00446030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 administered IV on Day 1 for Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 administered IV on Day 1 for Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
Study: NCT03783910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906
Description: One prolonged-release tablet containing 40 mg of GRT9906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GRT9906 tablets
Study: NCT04457921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep tissue massage
Description: DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
Study: NCT03003819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Collagen Wound Dressing
Description: Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Collagen Matrix
Description: Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
Study: NCT04203303

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT03679221

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study: NCT03853421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin
Description: The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin
Description: The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin
Description: The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
Study: NCT01796132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
Study: NCT03717740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
Study: NCT01244737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] FLT
Description: \[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] FLT
Description: \[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] FLT
Description: \[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
Study: NCT03547050

Intervention type: OTHER
Intervention: Blood draw
Description: Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

Intervention type: OTHER
Intervention: Existing samples
Description: Control DNA samples will be used that have been previously acquired in other studies.
Study: NCT02823912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesia calcinada
Study: NCT00874380

Intervention type: OTHER
Intervention: Increasing total fiber intake in patient's diet
Description: Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
Study: NCT01642355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention Consult
Description: In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consult & Behavioral Intervention
Description: In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
Study: NCT04273984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
Study: NCT03571464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGRO Mobile App
Description: GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGRO Mobile App
Description: GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards).
Study: NCT00356915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 100mg capsules
Description: Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200mg tablets
Description: Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
Study: NCT01916577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor mobilization of autologous CD117 stem cells
Description: Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor mobilization of autologous CD117 stem cells
Description: Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls